The Gill Center’s Lymphoma Program features a team of pediatric oncologists experienced in caring for children with any type of childhood Hodgkin and Non-Hodgkin lymphoma. These experts have access to regional, national and international clinical trials offering the latest treatment therapies – tailoring the therapy to provide the greatest chance to cure each patient. 

What We Treat

What We Treat

We treat all forms of pediatric Hodgkin and Non-Hodgkin lymphoma. As a group, lymphomas represent the third most common childhood cancer. We routinely treat Hodgkin lymphoma, which is the most common cancer in 15- to 19-year-olds, accounting for about 1,200 of the 1,700 cases of childhood lymphoma in the U.S. each year.

Non-Hodgkin lymphomas are a diverse group of malignancies, the more common of which are Burkitt lymphoma, diffuse large B cell lymphoma, and anaplastic large cell lymphoma. The breadth and depth of expertise within our program also allows us to treat patients with even the rarest Non-Hodgkin lymphomas. Over the past few years, we have developed treatment plans for adolescents with primary central nervous system lymphoma, follicular lymphoma, blastic plasmacytoid dendritic cell neoplasm, post- transplant lymphoproliferative diseases and others. 

Program Highlights

Program Highlights

  • Between 25 and 30 newly diagnosed patients each year
  • Experience in every form of childhood Hodgkin and non-Hodgkin lymphoma, from the most common to the rarest 
  • Opportunities to receive the most advanced therapies for childhood lymphoma through participation in clinical research 


Beyond Children's Oncology Group clinical trials, we conduct our own research. Current projects include: 

  • Early diagnosis of invasive fungal disease  and fungal prophylaxis in children with acute lymphoblastic and myelogenous leukemia
  • Identifying factors that predict risk for serious infection in children with leukemia 
  • Early phase clinical trials employing  new therapeutic agents to eradicate leukemia cells 
  • Laboratory research efforts at  UT Southwestern to understand  the biology of stem cells from  which leukemia begins  

Request Appointment

Complementary Content